As UCLA Health continues to participate in multiple CAR-T and other immunotherapy clinical trials, its apheresis unit and cell therapy lab continue to experience an increase in the need for their cell collection and processing services. Guest author, Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program, shares some of the…
As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…
As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. View this on-demand webinar for an in-depth discussion of standardization strategies that can bring efficiencies to the apheresis and collection infrastructure. Also included is a Q&A session…
Centers that collection patient cells feel crunch from growing demand. The arrival of CAR-T cancer treatments and the expected coming age of cell therapies are opening new frontiers for what medicines look like: Cells are taken from patients, then tweaked or supercharged in a lab, and finally given back to patients. Read this article to…
View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…
With the introduction of innovative cell and gene therapies to market, scalable commercial supply chain strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains. Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating…
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. Learn about scalability considerations when using cord blood. During this hour long on-demand webinar, our panelists discuss: Why it’s essential…
View Webinar Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for…
The ONE Forum 2021: On-demand session Over the last several years, there has been increasing global investment in the development of novel allogeneic cellular therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 novel allogeneic cellular therapies are under development across the globe, many of which are focused…